Table 2. Maximum severity of toxicity (Grade ≥ 3) for 14 gemcitabine-refractory patients receiving a total of 28 cycles of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone per patient.
| Classificationa | Frequency | ||
|---|---|---|---|
|
|
|||
| Cycle 1 (n=14) | Cycle 2 (n=8) | Overall (n=14) | |
| Neutropenia | 4 | 3 | 6 |
| Leukopenia | 3 | 1 | 4 |
| Infection | 2 | 2 | |
| Hypokalemia | 1 | 1 | |
| Fatigue | 2 | 3 | 5 |
| Febrile Neutropenia | 2 | 2 | |
| Anemia | 1 | 2 | 3 |
| Thrombocytopenia | 1 | 1 | 2 |
| Hypophosphatemia | 1 | 1 | |
| Hypoxia | 1 | 1 | 2 |
| Hypotension | 1 | 1 | |
| Ileus | 1b | 1b | |
| Thrombosis | 1 | 1 | |
| Dehydration | 1 | 1 | |
| Total Bilirubin | 1 | 1 | |
| Limb Edema | 1 | 1 | |
a
Based on National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0
b
Grade 5 event